Bristol-Myers Squibb, Celgene plan to combine in $74 billion deal
MLex Summary: Bristol-Myers Squibb announced plans to buy Celgene in a $74 billion transaction the company said will create a top focused specialty biopharma company with complementary areas of focus. The...To view the full article, register now.
Already a subscriber? Click here to view full article